1. Volume 128, Issue 2, Pages 313-327 (February 2005)
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients 
Kenneth E. Sherman, Norah J. Shire, Susan D. Rouster, Marion G. Peters, Margaret James Koziel, Raymond T. Chung, Paul S. Horn 
Gastroenterology 
Volume 128, Issue 2, Pages (February 2005)
DOI: /j.gastro
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Panel of model fit and observed viral loads over time for HCV/HIV co-infected patients with convergence. Viral load (log10 IU/mL) is shown on the y-axis. Days are shown on the x-axis. Dots represent observed values, solid line represents model fits. Fitted values are shown through the time points used in the model for each individual patient. (14 days for patients in this panel). The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Panel of model fit and observed viral loads over time for HCV monoinfected patients with convergence. Viral load (log 10 IU/mL) is shown on the y-axis. Days are shown on the x-axis. Dots represent observed values, solid line represents model fits. Fitted values are shown through the time points used in the model for each individual patient. For patients C03 and C10, using data from days 28 and 56 allowed much improved parameter estimation. The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 2
Panel of model fit and observed viral loads over time for HCV monoinfected patients with convergence. Viral load (log 10 IU/mL) is shown on the y-axis. Days are shown on the x-axis. Dots represent observed values, solid line represents model fits. Fitted values are shown through the time points used in the model for each individual patient. For patients C03 and C10, using data from days 28 and 56 allowed much improved parameter estimation. The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 3
HCV/HIV co-infected patients without model convergence. Viral load (log 10 IU/mL) is shown on the y-axis. Days are shown on the x-axis. Only observed values are shown. The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 4
HCV-monoinfected patients without model convergence. Viral load (log 10 IU/mL) is shown on y-axis. Days are shown on the x-axis. Only observed values are shown. The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

7. Figure 5
(A, B) Graphs using median kinetic parameters from genotype 1 patients to show delayed clearance in co-infected patients: all parameters (ϵ, c, δ, V0, t0) were calculated from the median pooled values of the study population for whom the model converged and who had viral clearance. The estimated V0 was 6.86 log10 IU/mL for co-infected and 5.88 log10 IU/mL for monoinfected patients. T0 was vs hours for co-infected and monoinfected patients, respectively; c was and 22.67/day, respectively; δ was .11 and .10/day, respectively; and ϵ was .76 and .81, respectively. These parameters were used to calculate λ1 and λ2 and the resulting pooled model fits. Solid line represents co-infected patients, dashed line represents monoinfected patients. The lower limit of assay detection is represented by the thin solid line at log10(600) IU/mL. (A) Early viral clearance (through 7 days). (B) Extension of model estimation through clearance (90 days). There is an approximately 20-day differential for predicted time to clearance between co-infected and monoinfected patients.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions